DBV Technologies S.A.
Research DBV Technologies S.A. (DBV) on Bullrun: market cap EUR 761.69M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDBV
- ExchangeF
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 761.69M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 50.40M
- Free cash flow-USD 53.00M
Valuation Snapshot
latest market cap is EUR 761.69M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 147.16M | -USD 121.72M | n/a | -1.05 | USD 194.17M | USD 7.99M | USD 168.78M |
| FY2024 | USD 0 | -USD 114.12M | n/a | n/a | -1.18 | USD 32.46M | USD 0 | USD 27.39M |
| FY2023 | USD 0 | -USD 72.71M | -USD 78.32M | n/a | -0.76 | USD 141.37M | USD 0 | USD 140.33M |
| FY2022 | USD 0 | -USD 96.01M | -USD 52.15M | n/a | -1.24 | USD 209.19M | USD 0 | USD 194.50M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 761.69M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is DBV Technologies S.A.'s market cap?
DBV Technologies S.A.'s market capitalization is EUR 761.69M.
What does DBV Technologies S.A. do?
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease.